Correction: Mapatumumab, a Fully Human Agonistic Monoclonal Antibody That Targets TRAIL-R1, in Combination with Gemcitabine and Cisplatin: A Phase I Study

In this article (Clin Cancer Res 2009;15:5584–90), which published in the September 1, 2009, issue of Clinical Cancer Research (1), in the Results section, General subsection, the third sentence should read, as follows: In addition, 15 patients received 124 cycles of mapatumumab monotherapy (median, 6; range, 2-48). Also, in the Results section, Pharmacokinetics subsection, first sentence of the last paragraph should read, as follows: Mean (with 95% confidence interval) exposure in cycles 1 and 2, as measured by Area Under the Curve C₀, AUC_0-∞, or AUC_last for gemcitabine, 2-difluoro-2-deoxyuridine, and cisplatin-derived unbound platinum is summarized by cohort in Supplementary Table S2. ARTICLE